SVN-AI-Enabled
discovery programme

Multiple novel chemical series generated via AI-enabled discovery, targeting serotonin, dopamine and noradrenaline transporters. The core engine for Solvonis’ preclinical pipeline, providing a renewable source of proprietary IP for expansion and future partnerships.